PPBT - Wutah bathi EPS kuartalan Purple Biotech Ltd.

Purple Biotech is developing a system to combat tumor drug resistance via its patented CM24 antibody. The percentage change in quarterly EPS reflects the market's interpretation of these achievements, where the 109.60 level captures fresh values. However, the risk of share dilution due to R&D costs persists, even though the company's molecules effectively suppress metastatic cancer defenses.

This metric measures the quarterly growth rate of earnings per share, reflecting the actual efficiency of business scaling without market distortions. For Purple Biotech (PPBT), which minimizes capital expenditures through the outsourcing of production and trials, the quarterly change in earnings per share serves as an indicator of operational flexibility and the ability to generate value at low costs.